Join the Tresiba group to help and get support from people like you.
Tresiba News
Technosphere Insulin + Insulin Degludec Noninferior to Usual Care in T1DM
MONDAY, Dec. 16, 2024 – For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior to usual care for glycemic control, according to a study...
Novo Nordisk to Lower U.S. List Prices for Tresiba and Fiasp by More Than 70%
PLAINSBORO, N.J., Dec. 05, 2024 – Novo Nordisk today announced plans to reduce the US list prices of two insulin products by more than 70% to better meet the needs of people living with diabetes....
Once-Weekly Efsitora Noninferior to Degludec for Type 2 Diabetes
FRIDAY, Sept. 13, 2024 – Once-weekly efsitora is noninferior to once-daily degludec for reducing glycated hemoglobin levels in adults with type 2 diabetes who have not received insulin, according to...
Inhaled Insulin Could Help Folks With Type 1 Diabetes Avoid Needles
MONDAY, June 24, 2024 – Inhaled insulin could be a better option than injections or pumps for some patients with type 1 diabetes, a new clinical trial shows. Patients using inhaled insulin (Afrezza)...
FDA Medwatch Alert: Novo Nordisk Issues Voluntary Nationwide Recall of Levemir, Tresiba, Fiasp, Novolog and Xultophy Product Samples Due to Improper Storage Temperature Conditions
May 10, 2021 – Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level. These products are b...
FDA Medwatch Alert: Caution When Using Pen Needles to Inject Medicines: FDA Safety Communication
Audience: Patients and caregivers who use or are considering using pen injectors with pen needles to inject prescription medicines. Health care providers who treat patients, or who train...
Novo Nordisk Receives FDA Approval of Tresiba (insulin degludec) for Use in Children and Adolescents With Diabetes
PLAINSBORO, N.J., Dec. 19, 2016 /PRNewswire/ – Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for...
Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection) for Type 2 Diabetes
PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ – Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for...
Further information
Related condition support groups
Diabetes, Type 2, Diabetes, Type 1, Diabetes Mellitus